Fox Run Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Fox Run Management’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-9,615	Closed	-$230K	–	989
2018 Q1	$230K	Buy	+9,615	New	+$303K	0.06%	587

Other funds holding ADMS

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fox Run Management's ADMS Position: Q2 2018 in Review

Fox Run Management sold out of Adamas Pharmaceuticals (ADMS) in Q2 2018, closing a stake of 9,615 shares — an estimated $230K sold.

Fox Run Management first reported a position in ADMS in Q1 2018 and held it in 1 quarter. The position peaked at $230K in Q1 2018. 126 funds tracked by Wall St. Rank hold ADMS as of Q2 2018.

Fox Run Management reported no remaining Adamas Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Fox Run Management sold 9,615 Adamas Pharmaceuticals shares in Q2 2018, an estimated $230K.
Fox Run Management first reported a position in Adamas Pharmaceuticals in Q1 2018 and held it in 1 quarter.
Fox Run Management's Adamas Pharmaceuticals position peaked at $230K in Q1 2018.
126 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2018.

Based on Fox Run Management's 13F filing for Q2 2018, filed 17 Jul 2018.